BCM
SUPN icon

Bridgeway Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Bridgeway Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.48M Sell
48,000
-10,000
-17% -$509K 0.05% 469
2025
Q4 		$2.88M Sell
58,000
-35,600
-38% -$1.73M 0.06% 405
2025
Q3 		$4.47M Sell
93,600
-28,300
-23% -$1.14M 0.1% 274
2025
Q2 		$3.84M Buy
121,900
+55,500
+84% +$1.78M 0.09% 304
2025
Q1 		$2.17M Buy
+66,400
New +$2.35M 0.05% 473
2019
Q2 		– Sell
-14,800
Closed -$519K – 1388
2019
Q1 		$519K Hold
14,800
– – 0.01% 1013
2018
Q4 		$492K Hold
14,800
– – 0.01% 1009
2018
Q3 		$745K Hold
14,800
– – 0.01% 1018
2018
Q2 		$886K Hold
14,800
– – 0.01% 915
2018
Q1 		$678K Sell
14,800
-700
-5% -$29.2K 0.01% 990
2017
Q4 		$618K Buy
15,500
+50
+0.3% +$1.98K 0.01% 1026
2017
Q3 		$618K Sell
15,450
-1,500
-9% -$64.9K 0.01% 1030
2017
Q2 		$731K Buy
16,950
+50
+0.3% +$1.78K 0.01% 957
2017
Q1 		$529K Buy
16,900
+5,800
+52% +$155K 0.01% 1054
2016
Q4 		$280K Buy
+11,100
New +$248K ﹤0.01% 1239
2015
Q2 		– Sell
-50,000
Closed -$605K – 1529
2015
Q1 		$605K Hold
50,000
– – 0.01% 1002
2014
Q4 		$415K Sell
50,000
-550
-1% -$4.62K 0.01% 1130
2014
Q3 		$439K Buy
50,550
+550
+1% +$4.97K 0.01% 1138
2014
Q2 		$548K Hold
50,000
– – 0.01% 1036
2014
Q1 		$447K Hold
50,000
– – 0.01% 1128
2013
Q4 		$377K Hold
50,000
– – 0.01% 1162
2013
Q3 		$367K Hold
50,000
– – 0.01% 1161
2013
Q2 		$322K Buy
+50,000
New +$294K 0.01% 1141

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's SUPN Position: Q1 2026 in Review

Bridgeway Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 17% in Q1 2026, selling an estimated $509K and leaving 48,000 shares worth $2.48M. The position accounts for 0.05% of the portfolio, ranked #469.

Bridgeway Capital Management first reported a position in SUPN in Q2 2013 and has held it in 23 quarters since. The position peaked at $4.47M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Bridgeway Capital Management held 48,000 shares of Supernus Pharmaceuticals worth $2.48M as of Q1 2026.
  • Bridgeway Capital Management sold 10,000 Supernus Pharmaceuticals shares in Q1 2026, an estimated $509K.
  • Supernus Pharmaceuticals made up 0.05% of Bridgeway Capital Management's portfolio in Q1 2026, its #469 holding.
  • Bridgeway Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 23 quarters since.
  • Bridgeway Capital Management's Supernus Pharmaceuticals position peaked at $4.47M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.